摘要
目的:探讨多发性骨髓瘤患者抗凝血酶(AT)活性变化及临床意义。方法:回顾性分析72例多发性骨髓瘤患者AT活性水平,并比较不同临床分期AT活性的差异,分析初发、缓解、未缓解、复发不同阶段AT活性的变化。结果:多发性骨髓瘤Ⅱ、Ⅲ期患者AT活性较Ⅰ期患者降低(P<0.05),初发组、部分缓解组、复发组较缓解组AT活性显著性降低(P<0.05);复发组白蛋白较缓解组降低,初发组、复发组、部分缓解组β2-MG、球蛋白及LDH均较缓解组升高,均差异有统计学意义(均P<0.05)。AT活性水平与β2-MG的变化具有相关性(r=-0.441,P<0.05);AT活性水平与白蛋白、球蛋白及LDH水平的变化无明确相关性。结论:AT活性不仅反映多发性骨髓瘤患者抗凝系统功能,也可反映患者整体病情变化,而且AT活性水平变化与β2微球蛋白具有相关性,可能具有一定的预后评估意义。
Objective：To assess the clinical value of antithrombin（AT） activity for multiple myeloma（MM） patients.Method：Seventy-two MM patients staging into Ⅰ,Ⅱor Ⅲ were divided into newly-diagnosed group,complete remission（CR） group,partial remission（PR） group or progression of disease（PD） group.Clinical data of AT,β2-microglobulin（β2-MG）,lactate dehydrogenase（LDH）,albumin（ALB） were analyzed retrospectively among these groups and normal control group.Result：For MM patients in stage Ⅱ and Ⅲ,AT activities were lower than those patients in stage Ⅰ（P0.05）.There was no significant difference in AT activity between stage Ⅱ and Ⅲ.AT activities of PD and PR groups were lower than CR group（P0.05）,but β2-MG of these groups were higher than CR group（P0.05）.There was negative correlation between AT activity and β2-MG level（r=-0.441,P0.05）.Conclusion：Determination of AT activity in patients with MM may be important for evaluating the effect of treatment and prognosis.
出处
《临床血液学杂志》
CAS
2011年第2期133-134,138,共3页
Journal of Clinical Hematology
